Financial Analysis: Eiger Biopharmaceuticals (EIGR) versus Aevi Genomic Medicine (GNMX)

Eiger Biopharmaceuticals (NASDAQ:EIGR) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Eiger Biopharmaceuticals and Aevi Genomic Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eiger Biopharmaceuticals N/A -127.50% -75.01%
Aevi Genomic Medicine N/A -206.46% -153.74%

Analyst Ratings

This is a summary of current recommendations for Eiger Biopharmaceuticals and Aevi Genomic Medicine, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eiger Biopharmaceuticals 0 0 7 0 3.00
Aevi Genomic Medicine 0 1 0 0 2.00

Eiger Biopharmaceuticals currently has a consensus target price of $34.14, indicating a potential upside of 209.55%. Given Eiger Biopharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Eiger Biopharmaceuticals is more favorable than Aevi Genomic Medicine.

Institutional & Insider Ownership

81.0% of Eiger Biopharmaceuticals shares are owned by institutional investors. Comparatively, 19.2% of Aevi Genomic Medicine shares are owned by institutional investors. 7.9% of Eiger Biopharmaceuticals shares are owned by company insiders. Comparatively, 11.7% of Aevi Genomic Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Eiger Biopharmaceuticals and Aevi Genomic Medicine’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eiger Biopharmaceuticals N/A N/A -$52.39 million ($3.82) -2.89
Aevi Genomic Medicine N/A N/A -$30.77 million ($0.83) -0.27

Eiger Biopharmaceuticals is trading at a lower price-to-earnings ratio than Aevi Genomic Medicine, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Eiger Biopharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.

Summary

Eiger Biopharmaceuticals beats Aevi Genomic Medicine on 7 of the 10 factors compared between the two stocks.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates that are in Phase II clinical trial include Lambda, which targets type III IFN receptors; Exendin 9-39 for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.